The US Food and Drug Administration (FDA) has sent a warning letter to Cadila Pharma over several manufacturing deficiencies at its Gujarat plant.
The plant has had manufacturing issues on multiple occasions, it said in a letter to the Rajiv-Modi led company, pointing out that more than the permitted level of impurities were allowed that were not adequately investigated.
The America drug regulator further pointed out that this was not the first time such poor practices were found to be exercised in the Gujarat plant.
Help employers find you! Check out all the jobs and post your resume.
